Provided by Tiger Trade Technology Pte. Ltd.

Ashland

50.81
+0.89001.78%
Pre-market: 51.310.5000+0.98%04:21 EDT
Volume:426.30K
Turnover:21.64M
Market Cap:2.33B
PE:-3.36
High:51.21
Open:49.35
Low:49.30
Close:49.92
52wk High:65.65
52wk Low:45.21
Shares:45.76M
Float Shares:41.77M
Volume Ratio:0.51
T/O Rate:1.02%
Dividend:1.65
Dividend Rate:3.25%
EPS(TTM):-15.1257
EPS(LYR):-18.3696
ROE:-29.98%
ROA:2.09%
PB:1.24
PE(LYR):-2.77

Loading ...

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

GlobeNewswire
·
Dec 07, 2025

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

GlobeNewswire
·
Dec 07, 2025

GENSCRIPT BIO (01548): Legend Announces Presentations at 2025 ASH Annual Meeting

Stock News
·
Dec 07, 2025

LEADS BIOLABS-B (09887): LBL-034 Clinical Data Presented at 67th ASH Annual Meeting

Stock News
·
Dec 07, 2025

Nurix Therapeutics (NRIX): Valuation Check After New NX-5948 Phase 1a/1b Data at ASH 2025

Simply Wall St.
·
Dec 07, 2025

Weekend Brings Positive News! Two Key Departments Release Major Updates

Deep News
·
Dec 07, 2025

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire
·
Dec 07, 2025

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire
·
Dec 06, 2025

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

GlobeNewswire
·
Dec 06, 2025

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

GlobeNewswire
·
Dec 06, 2025

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

GlobeNewswire
·
Dec 06, 2025

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

GlobeNewswire
·
Dec 06, 2025

Ashland (ASH): Reassessing Valuation After Major Investor Discloses 5.7% Stake and Fuels Bullish Sentiment

Simply Wall St.
·
Dec 06, 2025

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire
·
Dec 06, 2025

13D Filings -- Barrons.com

Dow Jones
·
Dec 06, 2025

Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Benzinga_recent_news
·
Dec 06, 2025

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

GlobeNewswire
·
Dec 05, 2025

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

GlobeNewswire
·
Dec 05, 2025

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET

GlobeNewswire
·
Dec 04, 2025

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

GlobeNewswire
·
Dec 04, 2025